Article
Oncology
Miriam Valenzuela-Cardenas, Cody Gowan, Parker Dryja, Mee Y. Bartee, Eric Bartee
Summary: This study generated a doubly recombinant oncolytic virus that expresses PD1 and IL-12 fusion protein to treat solid tumors. The results revealed that the inflammation induced by the virus during therapy has a dual effect, and blocking the TNF pathway can enhance the therapeutic efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Tianyue Chen, Xiangqing Ding, Qibin Liao, Nan Gao, Ye Chen, Chen Zhao, Xiaoyan Zhang, Jianqing Xu
Summary: Through this study, IL-21 and TTV were identified as the most potent immunomodulatory molecule and oncolytic virus for solid tumor suppression in mouse models. A novel recombinant oncolytic virus resulting from their combination, namely rTTV Delta TK-mIL21, showed significant anti-tumor activity in mice.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Miika Martikainen, Mohanraj Ramachandran, Roberta Lugano, Jing Ma, Minttu-Maria Martikainen, Anna Dimberg, Di Yu, Andres Merits, Magnus Essand
Summary: The study constructed an IFN-I-resistant SFV-AM6 virus that induced immunogenic apoptosis in GL261 cells and showed therapeutic potency against glioma. Additionally, combination therapy with SFV-AM6-124T and antiPD1 immunotherapy promoted an inflammatory response and increased tumor-reactive CD8(+) cells in the GL261 glioma model.
MOLECULAR THERAPY-ONCOLYTICS
(2021)
Article
Oncology
Bangxing Hong, Upasana Sahu, Matthew P. Mullarkey, Evan Hong, Guangsheng Pei, Yuanqing Yan, Yoshihiro Otani, Yeshavanth Banasavadi-Siddegowda, Huihui Fan, Zhongming Zhao, Jianhua Yu, Michael A. Caligiuri, Balveen Kaur
Summary: PKR is a major barrier to oncolytic herpes simplex virus (oHSV) therapy, as it inhibits antiviral immune response. The activation of PKR also induces TGF-beta signaling, suppressing antitumor immune responses. Therefore, targeting PKR with an oncolytic virus significantly improves virotherapy response.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Mathematics
Jing Li, Yifu Wang
Summary: This paper focuses on a haptotactic cross-diffusion system as a model for oncolytic virotherapy, examining the influence of the extracellular matrix (ECM) on the interaction between tumor cells and oncolytic viruses. The main results demonstrate the global boundedness of solutions to the associated two-dimensional initial-boundary value problems under suitable assumptions on the system parameters.
JOURNAL OF DIFFERENTIAL EQUATIONS
(2021)
Article
Oncology
Shuxin Sun, Yang Liu, Chaobin He, Wanming Hu, Wenfeng Liu, Xin Huang, Jiali Wu, Fengxiao Xie, Chen Chen, Jun Wang, Yuan Lin, Wenbo Zhu, Guangmei Yan, Jing Cai, Shengping Li
Summary: NanoKnife, a nonthermal ablation technique, combined with M1 virus shows synergistic therapeutic efficacy in treating locally advanced pancreatic cancer, enhancing tumor inhibition and prolonging survival in immunocompetent mice. The combination promotes M1 infection, converting immune-silent tumors into immune-inflamed tumors and potentially improving prognosis for LAPC patients.
Article
Oncology
Victoria Roulstone, David Mansfield, Robert J. Harris, Katie Twigger, Christine White, Johann de Bono, James Spicer, Sophia N. Karagiannis, Richard Vile, Hardev Pandha, Alan Melcher, Kevin Harrington
Summary: The study found that patients' responses to reovirus infection are largely unaffected by the concomitant drug treatments tested, providing confidence that RNA viral treatment or infection is compatible with standard of care treatments.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Cell Biology
Jessica A. Minott, Jacob P. van Vloten, Lily Chan, Yeganeh Mehrani, Byram W. Bridle, Khalil Karimi
Summary: This study investigated the role of neutrophils in oncolytic Orf-virus-mediated immunotherapy in a murine model of pulmonary melanoma metastases, revealing their crucial contribution to tumor regression.
Article
Oncology
Weiyi Wang, Shuaitong Liu, Peihong Dai, Ning Yang, Yi Wang, Rachel A. Giese, Taha Merghoub, Jedd Wolchok, Liang Deng
Summary: The study compared the antitumor effects of live oncolytic vaccinia viruses versus the inactivated versions and found that the inactivated versions are more effective in inducing systemic antitumor immunity, depending on Batf3-dependent CD103(+) dendritic cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Cell Biology
Eleni Kalafati, Ekati Drakopoulou, Nicholas P. Anagnou, Kalliopi I. Pappa
Summary: Cervical cancer is a major global malignancy in women. Current therapies are inadequate and cytotoxic, leading to serious side effects. Oncolytic viruses offer a promising treatment option as they selectively infect and kill cancer cells. This review discusses different oncolytic viruses for targeting cervical cancer and their combination with conventional therapies.
Review
Immunology
Matin Ghasemi, Laleh Abbasi, Leila Ghanbari Naeini, Pajman Kokabian, Najmeh Nameh Goshay Fard, Nozar Givtaj
Summary: Every type of cancer tissue is more susceptible to viral infection, which has been utilized as a new anti-cancer therapy using oncolytic viruses (OVs). OVs selectively infect and destroy cancer cells while causing no harm to the host. Research focuses on the interaction between OVs and the host immune system, particularly the role of dendritic cells (DCs) and natural killer (NK) cells in the therapeutic response.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Mathematics, Applied
Yifu Wang, Chi Xu
Summary: This paper deals with an initial-boundary value problem for a doubly haptotactic crossdiffusion system arising from the oncolytic virotherapy. It demonstrates the existence of a unique global classical solution under certain conditions, leading to the stabilization of the system towards a spatially homogeneous equilibrium.
MATHEMATICAL MODELS & METHODS IN APPLIED SCIENCES
(2023)
Article
Mathematics
Jiashan Zheng, Jianing Xie
Summary: This paper deals with a model for oncolytic virotherapy, which can simulate the process of oncolytic viral therapy, and provides the main results on the global boundedness of the system solutions.
JOURNAL OF DIFFERENTIAL EQUATIONS
(2022)
Article
Immunology
Almohanad A. Alkayyal, Reham Ajina, Marco Cacciabue, Aaesha A. Alkayyal, Nizar H. Saeedi, Taofik Hussain Alshehry, Feras Kaboha, Mohammed A. Alotaibi, Nada Zaidan, Khalid Shah, Fayhan Alroqi, Ahmad Bakur Mahmoud
Summary: Despite recent advances in oncolytic virus research, improving their replication is crucial for enhancing their therapeutic index. This study found that the SARS-CoV-2 spike protein receptor-binding domain (RBD) can enhance viral production and anticancer activity of oncolytic viruses.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Molly C. Holbrook, Dakota W. Goad, Valery Z. Grdzelishvili
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with poor prognosis and a dismal survival rate, expected to become the second leading cause of cancer-related deaths in the United States. Oncolytic virus (OV) is an anticancer approach that utilizes replication-competent viruses to preferentially infect and kill tumor cells. Vesicular stomatitis virus (VSV), one such OV, is already in several phase I clinical trials against different malignancies. VSV-based recombinant viruses are effective OVs against a majority of tested PDAC cell lines. However, some PDAC cell lines are resistant to VSV. Mechanisms such as upregulated type I IFN signaling and inefficient viral attachment play a role in this resistance, but alternative approaches like combining VSV with JAK1/2 inhibitors have shown promise in overcoming this resistance.
Review
Oncology
Mark Aleynick, Judit Svensson-Arvelund, Christopher R. Flowers, Aurelien Marabelle, Joshua D. Brody
CLINICAL CANCER RESEARCH
(2019)
Article
Biochemistry & Molecular Biology
Linda Hammerich, Thomas U. Marron, Ranjan Upadhyay, Judit Svensson-Arvelund, Maxime Dhainaut, Shafinaz Hussein, Yougen Zhan, Dana Ostrowski, Michael Yellin, Henry Marsh, Andres M. Salazar, Adeeb H. Rahman, Brian D. Brown, Miriam Merad, Joshua D. Brody
Article
Immunology
Lisa Nika, Sara Cuadrado-Castano, Guha Asthagiri Arunkumar, Clemens Gruenwald-Gruber, Meagan McMahon, Krisztina Koczka, Adolfo Garcia-Sastre, Florian Krammer, Reingard Grabherr
Article
Oncology
Netonia Marshall, Keino Hutchinson, Thomas U. Marron, Mark Aleynick, Linda Hammerich, Ranjan Upadhyay, Judit Svensson-Arvelund, Brian D. Brown, Miriam Merad, Joshua D. Brody
Article
Cell Biology
Noemi Garcia-Romero, Irina Palacin-Aliana, Susana Esteban-Rubio, Rodrigo Madurga, Sergio Rius-Rocabert, Josefa Carrion-Navarro, Jesus Presa, Sara Cuadrado-Castano, Pilar Sanchez-Gomez, Adolfo Garcia-Sastre, Estanislao Nistal-Villan, Angel Ayuso-Sacido
Article
Oncology
Ranjan Upadhyay, Jonathan A. Boiarsky, Gvantsa Pantsulaia, Judit Svensson-Arvelund, Matthew J. Lin, Aleksandra Wroblewska, Sherry Bhalla, Nathalie Scholler, Adrian Bot, John M. Rossi, Norah Sadek, Samir Parekh, Alessandro Lagana, Alessia Baccarini, Miriam Merad, Brian D. Brown, Joshua D. Brody
Summary: The study revealed the crucial role of Fas-FasL in T cell killing of tumors and the bystander killing of antigen-negative tumor cells. This new finding may enhance the efficacy of immunotherapies and prevent cancer relapse by targeting both antigen expression and antigen-loss variants.
Review
Immunology
Vicent Tur-Planells, Adolfo Garcia-Sastre, Sara Cuadrado-Castano, Estanislao Nistal-Villan
Summary: This review provides an overview of non-human-adapted RNA viruses used in cancer therapy and the diverse strategies employed to optimize their therapeutic capabilities. Through this article, we gain insights into the promising advancements in virotherapy and its potential to revolutionize cancer treatment.
Article
Oncology
Aryana Javaheri, Yonina Bykov, Ignacio Mena, Adolfo Garcia-Sastre, Sara Cuadrado-Castano
Summary: The study highlights the promising oncolytic properties of APMV-4 Duck/Hong Kong/D3/1975 virus in murine colon carcinoma and melanoma tumor models, surpassing the therapeutic potential of NDV. Additionally, recombinant APMV-4 viruses have demonstrated significant antitumor capabilities, paving the way for the development of next-generation viral therapeutics.
CANCER RESEARCH COMMUNICATIONS
(2022)